In Vitro and In Vivo Anticancer Activity of Gimatecan against Hepatocellular Carcinoma

Document Type: Research Articles

Authors

1 Lees Pharmaceuticals

2 CVie Therapeutics Limited, Taiwan,

3 Zhaoke Pharmaceutical (Heifei) Co. Limited, Hefei, China

4 Lee's Pharmaceutical (Hong Kong) Limited

Abstract

 
Objective: Gimatecan is a new camptothecin (CPT) analogue that inhibits tumor growth by targeting DNA topoisomerase I (TOP I) and introducing strong and persistent DNA cleavage. Anti-tumor activity has been demonstrated with a wide range of solid tumors in previous preclinical and clinical studies. Here, we investigated for the first time the effects of gimatecan on the proliferation of hepatocellular carcinoma (HCC) cells both in vitro and in vivo. Methods: Anticancer efficacy of gimatecan were evaluated in a panel of HCC cell lines and corresponding mouse xenograft models. Inhibition of cell proliferation was measured by CellTiter-Glo cell viability assay. In vivo, gimatecan and control preparations were orally administered every four days, for a total of four times. Tumor volume and body weights of the mice were measured twice weekly. Results: In vitro cytotoxicity evaluation showed that gimatecan inhibited the proliferation of a large panel of HCC cell lines in a dose dependent manner, with IC50 values ranging between 12.1~1085.0 nM. In vivo evaluation in mouse xenograft models showed significant antitumor effects of gimatecan at 0.8mg/kg and 0.4mg/kg as compared to the control group. Conclusion: This study suggested that gimatecan may have the potential to be used as a chemotherapeutic agent for the treatment of HCC.

Keywords

Asian Pacific Journal of Cancer Prevention

Volume 17, Issue 11
November 2016
Pages 4853-4856

Files

History

  • Receive Date: 22 August 2016
  • Revise Date: 14 November 2016
  • Accept Date: 28 December 2016

Share

How to cite

Statistics